Clinical trial
A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma
NCT03335098 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma
- Lead sponsor
- Seoul National University Hospital
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- November 21, 2016
- Completion date
- December 31, 2020
- Enrollment
- 15 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
lymphoplasmacytic lymphoma, waldenstrom macroglobulinemia